Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown. Of 130 consecutive patients with a diagnosis of PBC, we identified 12 cases (9.2%) of overlap syndrome (10 females, 2 males; median age, 50 years) strictly defined by the presence of at least two of the three recognized biochemical, serological, and histological criteria of each disease. One patient had initially pure PBC and developed AIH characterized by a flare of alanine transaminase (ALT) (1,330 IU/L; N < 35), elevated immunoglobulin G (IgG) (42 g/L; N < 14.0), and presence of anti-smooth muscle antibodies (ASMA) after 20 months of ursodeoxycholic acid (UDCA) therapy. A complete clinical and biochemical remission was achieved under combination of corticosteroids and UDCA. Eleven patients had features of both diseases at presentation: high serum levels of alkaline phosphatase (AP) (median: 280 IU/L; N < 100), ALT (140 IU/L), and IgG (30.8 g/L), presence of mitochondrial antibodies (n = 9) or ASMA (n = 9), florid bile duct lesions (n = 8), and moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (n = 11). UDCA (13-15 mg/kg/d) given alone in 5 patients induced a significant decrease in biochemical cholestasis but not in ALT levels, and liver fibrosis progressed in 3 patients. Corticosteroids given alone in 6 patients induced a significant decrease in ALT, IgG, and AP levels, but none had a biochemical normalization. The patients with persistently abnormal liver tests under either UDCA or corticosteroids received both UDCA and corticosteroids. A further marked biochemical improvement was observed, and all patients became asymptomatic. We conclude that, in patients with PBC: 1) overlap syndrome with AIH is not rare; 2) flares of AIH may occur either spontaneously or under UDCA; and 3) combination of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response. Overlap syndrome may represent an important and unrecognized cause of resistance to UDCA in patients with PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The available data suggest that patients who fulfil the Paris criteria for the diagnosis of AIH either at presentation or during the course of their PBC may benefit from additional immunosuppression in the short-and medium-term [160,162,175,176].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [162]
In the citing paper
“A simplified AIH scoring system has more recently been developed, and, when applied to PBC patients, it identified fewer patients meeting probable AIH criteria than the older scoring system did (4% versus 12%).(125)(126)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [126]
In the citing paper
“Criteria have been proposed by the Paris group for ‘true’ PBC/AIH overlap,272 with two out of three of (a) ALT >5 x ULN, (b) IgG >2 x ULN or positive anti-SMA and (c) liver biopsy with ‘moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (interface hepatitis)’ being suggested as diagnostic of overlap in the context of a PBC diagnosis.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [272]
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Calmus, Y., Gane, P., Rouger, P., & Poupon, R. (1990) · Hepatology · doi:10.1002/hep.1840110104 · Cited by 303
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Research works printed but not linked: 2
- Shouval, 1979, Chronic active hepatitis with cholestatic features, Am J Gastroenterol, 72, 542
- Nakamura, 1995, Effect of ursodeoxycholic acid (UDCA) on patients with type 1 auto-immune hepatitis [Abstract], Gastroenterology, 107, 958A
Cited by
Items 201–300 of 743
Treatment of Autoimmune Hepatitis
Strassburg, C. P., & Manns, M. P. (2009) · Seminars in Liver Disease · doi:10.1055/s-0029-1233534 · Cited by 43
“These treatments can be combined when biochemistry and histology suggest a relevant additional disease component.(60) Validated therapeutic guidelines for overlap syndromes are not available.”
Jiang, R., Tang, J., Zhang, X., He, Y., Yu, Z., Chen, S., Xia, J., Lin, J., & Ou, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810671 · Cited by 44
The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis
Özaslan, E., Efe, C., & ÖZASLAN, N. G. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.06.001 · Cited by 41
Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)
You, H., Duan, W., Li, S., Lv, T., Chen, S., Lu, L., Ma, X., Han, Y., Nan, Y., Xu, X., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00347 · Cited by 46
Therapeutic Potential of IL‐17‐Mediated Signaling Pathway in Autoimmune Liver Diseases
Zhang, H., Bernuzzi, F., Lleò, A., Ma, X., & Invernizzi, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/436450 · Cited by 38
“These patients are often referred to as “overlap syndromes” [1, 2].”
BackgroundPapastergiou, V., Tsochatzis, E. A., Rodríguez‐Perálvarez, M., Thalassinos, E., Pieri, G., Manousou, P., Germani, G., Rigamonti, C., Arvaniti, V., Karatapanis, S., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12522 · Cited by 39
Bossen, L., Gerussi, A., Lygoura, V., Mells, G. F., Carbone, M., & Invernizzi, P. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.02.013 · Cited by 35
Lian, J., Liu, W., Hao, S., Chen, D., Wang, Y., Yang, J.-L., Jia, H., & Huang, J. (2015) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(15)60393-9 · Cited by 37
Additional fibrate treatment in UDCA‐refractory PBC patients
Chung, S. W., Lee, J., Kim, M. A., Leem, G., Kim, S. W., Chang, Y. W., Lee, H. Y., Yoon, J. S., Park, J. Y., Lee, Y. B., et al. (2019) · Liver International · doi:10.1111/liv.14165 · Cited by 35
Palmer, M., Regev, A., Lindor, K. D., Avigan, M., Dimick‐Santos, L., Treem, W. R., MARCINAK, J. F., Lewis, J. H., Anania, F. A., Seekins, D. W., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15579 · Cited by 34
Transitions between variant forms of primary biliary cirrhosis during long-term follow-up
Lindgren, S. C., Glaumann, H., Almer, S. H., Bergquist, A. M., Bjornsson, E. S., Broomé, U., Danielsson, Å., Lebrun, B., Prytz, H., & Olsson, R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2008.12.011 · Cited by 35
“The recognition of these clinically distinct entities has important implications not only from a classification standpoint but also for management and a better understanding of the pathophysiology of autoimmune liver diseases [12,16].”
BackgroundDiagnosis and Management of Overlap Syndromes
Bunchorntavakul, C., & Reddy, K. R. (2014) · Clinics in Liver Disease · doi:10.1016/j.cld.2014.09.005 · Cited by 44
“Although UDCA therapy alone may induce biochemical responses in some patients with AIH-PBC overlap,(26) most patients may require a combination of UDCA and immunosuppressive therapy to obtain a complete response.(24,38,39) In the”
BackgroundMethodBoonstra, K., Bokelaar, R., Stadhouders, P. H. G. M., Tuynman, H. A. R. E., Poen, A. C., van Nieuwkerk, K. M., Witteman, E. M., Hamann, D., Witteman, B. J. M., Beuers, U. H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9530-z · Cited by 36
Role of Auto-Antibodies for the Diagnosis of Chronic Cholestatic Liver Diseases
Terjung, B., & Spengler, U. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:115 · Cited by 38
Nguyen, H. H., Shaheen, A. A., Baeza, N., Lytvyak, E., Urbanski, S. J., Mason, A. L., Norman, G. L., Fritzler, M. J., & Swain, M. G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193960 · Cited by 36
Chazouillères, O. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80021-5 · Cited by 34
Self-citationSequential presentation of primary biliary cirrhosis and autoimmune hepatitis
Efe, C., Ozaslan, E., Heurgué-Berlot, A., Kav, T., Masi, C., Purnak, T., Torgutalp, M., Muratori, L., Bresson-Hadni, S., Thiéfin, G., et al. (2014) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000075 · Cited by 32
Dinani, A. M., Fischer, S. E., Mosko, J., Guindi, M., & Hirschfield, G. M. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.010 · Cited by 32
Kobayashi, M., Kakuda, Y., Harada, K., Sato, Y., Sasaki, M., Ikeda, H., Terada, M., Mukai, M., Kaneko, S., & Nakanuma, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i13.3597 · Cited by 34
Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
Kowdley, K. V., Bowlus, C. L., Levy, C., Mayo, M. J., Pratt, D. S., Vuppalanchi, R., & Younossi, Z. M. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002070 · Cited by 35
“Recent studies on liver biopsy specimens from patients with PBC have demonstrated loss of the canals of Hering to be the earliest histologic change associated with PBC, with characteristic diagnostic fi ndings becoming evident after this histologic fi nding (11,12).”
BackgroundTreatment in primary biliary cholangitis: Beyond ursodeoxycholic acid
van Hooff, M. C., Werner, E., & van der Meer, A. J. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.030 · Cited by 32
Diagnosis and Treatment of Autoimmune Hepatitis
Vierling, J. M. (2011) · Current Gastroenterology Reports · doi:10.1007/s11894-011-0236-2 · Cited by 33
“A retrospective study concluded that the Paris criteria [34] had a sensitivity of 92% and specificity of 97% for the diagnosis of PBC-AIH overlap syndrome [35].”
BackgroundCeliac Disease-Associated Autoimmune Cholangitis
Sedlack, R. E., Smyrk, T. C., Czaja, A. J., & Talwalkar, J. A. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.07131.x · Cited by 32
“In terms of selecting an appropriate therapeutic approach for AIC, there have been reports of biochemical improvement with ursodeoxycholic acid and immunosuppressive agents (15).”
BackgroundRiveiro‐Barciela, M., Barreira‐Díaz, A., Esteban, P., Rota, R., Álvarez‐Navascués, C., Pérez-Medrano, I., Mateos, B., Góméz, E., De‐la‐Cruz, G., Ferre‐Aracil, C., et al. (2024) · Liver International · doi:10.1111/liv.15970 · Cited by 37
Fan, X., Yin, D., Men, R., Xu, H., & Yang, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00346 · Cited by 32
“Individuals were included if they met the criteria for definite or probable AIH based on the revised criteria published by the International AIH Group in 1999; AIH – PBC variant syndrome was diagnosed according to the Paris criteria (Chazouilleres et al., 1998).”
MethodBurghart, L., Halilbasic, E., Schwabl, P., Simbrunner, B., Stättermayer, A. F., Petrenko, O., Scheiner, B., Bauer, D. J. M., Pinter, M., Boztuǧ, K., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01839-3 · Cited by 34
“Prevalence of PBC-AIH-Overlap, which was diagnosed according to the PARIS criteria [39], was considerably higher in our cohort when compared to preexisting litera-”
MethodResultAutoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis
Himoto, T., & Nishioka, M. (2013) · Autoimmunity Highlights · doi:10.1007/s13317-013-0046-7 · Cited by 37
Autoimmune Hepatitis Overlap Syndromes and Liver Pathology
Czaja, A. J., & Carpenter, H. A. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.01.008 · Cited by 34
“Laboratory resolution (67 vs 27%) has also occurred more commonly than in patients treated with corticosteroids or UDCA alone, albeit the experience has been small.(15) Patients”
BackgroundYasunami, M., Nakamura, H., Tokunaga, K., Kawashima, M., Nishida, N., Hitomi, Y., & Nakamura, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-11148-6 · Cited by 32
Gish, R. G., & Mason, A. L. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70167-7 · Cited by 33
Yoshioka, Y., Taniai, M., Hashimoto, E., Haruta, I., & Shiratori, K. (2013) · Hepatology Research · doi:10.1111/hepr.12210 · Cited by 32
Recent advances in the diagnosis and treatment of primary biliary cholangitis
Huang, Y.-Q. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i33.1419 · Cited by 31
Katsushima, F., Takahashi, A., Sakamoto, N., Kanno, Y., Abe, K., & Ohira, H. (2013) · Hepatology Research · doi:10.1111/hepr.12198 · Cited by 30
Guo, C., Zhang, H., Yang, J., Zhu, R., Zheng, Y., Dai, W., Wang, F., Chen, K., Li, J., Wang, C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s74515 · Cited by 37
Zen, Y., Harada, K., Sasaki, M., Tsuneyama, K., Matsui, K., Haratake, J., Sakisaka, S., Maeyama, S., Yamamoto, K., Nakano, M., et al. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-004-1514-7 · Cited by 31
Lee, H., Stapp, R., Ormsby, A., & Shah, V. V. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpe93gzshuntai · Cited by 30
Clinical and biochemical features of autoimmune hepatitis in 36 pediatric patients
Bellomo‐Brandão, M. A., da Costa-Pinto, E. A. L., Tommaso, A. M. A. D., & Hessel, G. (2006) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032006000100012 · Cited by 34
Clinical practice guidelines for autoimmune hepatitis
Ohira, H., Takahashi, A., Zeniya, M., Abe, M., Arinaga‐Hino, T., Joshita, S., Takaki, A., Nakamoto, N., Kang, J., Suzuki, Y., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13776 · Cited by 32
Zhu, G., Shi, K., Huang, S., Huang, G., Lin, Y.-Q., Zhou, Z., Braddock, M., Chen, Y., & Zheng, M. (2015) · Medicine · doi:10.1097/md.0000000000000609 · Cited by 32
Kaplan, M. M., Bonder, A., Ruthazer, R., & Bonis, P. A. L. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1291-5 · Cited by 30
“Of interest, none of these patients met the diagnostic criteria for autoimmune chronic hepatitis as defined by Chazouilleres ((1) ALT levels C5 times the upper limit of normal, (2) serum immunoglobulin levels C2 times the upper limit of normal or a positive antismooth-muscle antibody test, and (3) a liver biopsy showi…”
BackgroundChan, A. W. H., Chan, R., Wong, G. L., Wong, V. W., Choi, P. C., Chan, H. L., & To, K. (2014) · Histopathology · doi:10.1111/his.12384 · Cited by 31
“However, an AIH–PBC overlap patient was excluded from our cohort in the initial selection and none of the 58 recruited patients met the criteria of the overlap syndrome as defined by Chazouill eres et al.(22) The prognostic utility of the Japanese grading system is probably limited in pure PBC patients.”
ResultFallatah, H. I., & Akbar, H. O. (2012) · Autoimmune Diseases · doi:10.1155/2012/312817 · Cited by 31
“HCC is much less commonly reported in AIH patients compared to other causes of liver cirrhosis [10–226].”
BackgroundPathophysiology and Diseases of the Proximal Pathways of the Biliary System
Nakanishi, Y., & Saxena, R. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0229-ra · Cited by 30
“A PBC-AIH overlap syndrome has been reported.(15) It has been proposed that the diagnosis of PBC-AIH overlap syndrome should be made if 2 of 3 characteristic features of PBC (alkaline phosphatase elevation 5 times above normal, presence of serum AMA, and florid duct lesion) and AIH (alanine aminotransferase elevation…”
BackgroundMethodvan den Brand, F. F., van Nieuwkerk, C. M. J., Verwer, B. J., de Boer, Y. S., de Boer, N. K. H., Mulder, C. J. J., Bloemena, E., Bakker, C. M., Vrolijk, J. M., Drenth, J. P. H., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14939 · Cited by 31
“The AIH variant with features of primary biliary cholangitis (AIH‐ PBC) was defined according to the “Paris criteria as AIH with an anti‐mitochondrial antibodies (AMA) titer of >1:80 in combination with compatible histology”.(11) AMA negative AIH patients with clinical and histopathological features of PBC were define…”
MethodHistological grading and staging in chronic hepatitis: Its practical correlation
Nakaji, M., Hayashi, Y., Ninomiya, T., Yano, Y., Yoon, S., Seo, Y., Nagano, H., Komori, H., Hashimoto, K., Orino, A., et al. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01410.x · Cited by 28
Variant syndromes of autoimmune hepatitis
Heathcote, J. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00031-4 · Cited by 29
“Chazouilleres et al [3] devised their own scoring system to assess retrospectively the frequency of AIH in 132 patients with AMA-positive PBC.”
BackgroundMethodPariente, A. E., Chazouillères, O., Causse, X., Hanslik, B., Arpurt, J., Henrion, J., Rosa, I., Renou, C., Garioud, A., & Corpechot, C. (2021) · PubMed · doi:10.1097/meg.0000000000002011 · Cited by 3
Self-citationPrimary biliary cirrhosis and bile acids
Corpechot, C. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70016-5 · Cited by 28
Primary biliary cirrhosis: proposal for a new simple histological scoring system
Wendum, D., Boëlle, P., Bédossa, P., Zafrani, E., Charlotte, F., Saint‐Paul, M., Michalak, S., Chazouillères, O., & Corpechot, C. (2014) · Liver International · doi:10.1111/liv.12620 · Cited by 28
“Patients with overlap syndrome as previously defined (19), positive hepatitis B or hepatitis C serology were excluded.”
BackgroundSelf-citationPark, Y., Cho, Y., Cho, E. J., & Kim, Y. J. (2015) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2015.21.2.150 · Cited by 29
“For the diagnosis of PBC, at least two features of PBC according to the Paris criteria should be satisfied as follows; (1) serum alkaline phosphatase (ALP) > 2 times upper limit of normal (ULN) or gamma-glutamyl transpeptidase (GGT) > 5 times ULN; (2) a positive test for AMA; and (3) a liver biopsy showing florid bile…”
MethodPrimary Biliary Cholangitis and Autoimmune Hepatitis
González, R. S., & Washington, K. M. (2018) · Surgical pathology clinics · doi:10.1016/j.path.2018.02.010 · Cited by 42
de Veer, R. C., Harms, M. H., Corpechot, C., Thorburn, D., Invernizzi, P., Janssen, H. L. A., Battezzati, P. M., Nevens, F., Lindor, K. D., Floreani, A., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17226 · Cited by 26
Gut microbial profile of treatment-naive patients with primary biliary cholangitis
Zhou, Y.-J., Ying, G.-X., Dong, S.-L., Xiang, B., & Jin, Q.-F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126117 · Cited by 26
Risk factors for hepatic decompensation in patients with primary biliary cirrhosis
Shi, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i7.1111 · Cited by 30
Imaging of autoimmune hepatitis and overlap syndromes
Malik, N., & Venkatesh, S. K. (2016) · Abdominal Radiology · doi:10.1007/s00261-016-1019-x · Cited by 29
Zhang, X., Chen, P., Gao, H., Hao, S., Yang, M., Zhao, H., Hu, J., Ma, W., & Li, L. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/5108781 · Cited by 28
UEG Week 2016 Poster Presentations
Dargienė, G., Kupčinskas, J., Jonaitis, L. V., Urbonas, V., Aužbikienė, R., Frandsen, T. H., Kučinskienė, R., Kaduševičius, E., Kupčinskas, L., & Andersen, L. P. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616663689 · Cited by 27
Honda, M., Kawai, H. F., Shirota, Y., Yamashita, T., Takamura, T., & Kaneko, S. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.03.009 · Cited by 26
Presentation and Diagnosis of Primary Biliary Cirrhosis in the 21st Century
Kumagi, T., & Onji, M. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.014 · Cited by 27
Enrique, C.-A., Julio, G., Misael, U., & Aldo, T. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31583-2 · Cited by 25
The many faces and pathologic diagnostic challenges of autoimmune hepatitis
Zhang, X., & Jain, D. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.06.019 · Cited by 27
Oliveira (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1060w · Cited by 25
“The expression “overlapping syndrome” has been used to describe forms of auto-immune disease, generally AIH/PBC or AIH/PSC, that present typical characteristics of more than one condition in the same patient, occurring simultaneously or sequentially, and sometimes migrating from one to another clinical presentation [3…”
BackgroundZhang, Y., Lu, J., Dai, W., Wang, F., Shen, M., Yang, J., Zhu, R., Zhang, H., Chen, K., Cheng, P., et al. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/490731 · Cited by 25
“…alkaline phosphatase (AP) levels at least two times higher than the upper limit of normal (ULN) or 𝛾-glutamyltranspeptidase (GGT) levels at least five times higher than the ULN; (2) a positive test for antimitochondrial antibodies; and (3) a liver biopsy specimen showing florid bile duct lesions.”
BackgroundInfluentialCheung, K. S., Seto, W., Fung, J., Lai, C., & Yuen, M. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2017.23 · Cited by 26
KASL clinical practice guidelines for management of autoimmune hepatitis 2022
(2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0087 · Cited by 26
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24
Gisbert, J. P., Jones, E. A., Pajares, J. M., & Moreno‐Otero, R. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01381.x · Cited by 28
Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases
Silveira, M. G., & Lindor, K. D. (2007) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.1.2.329 · Cited by 25
Liu, F., Pan, Z. G., Ye, J., Xu, D., Guo, H., Li, G. P., Xu, K. S., Hou, X. H., & Song, Y. H. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12196 · Cited by 23
Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy
Stoelinga, A., Biewenga, M., Drenth, J. P. H., Verhelst, X., van der Meer, A. J. P., de Boer, Y. S., Bouma, G., de Vries, E. S., Verdonk, R. C., van den Berg, A. P., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101088 · Cited by 28
“3,4 9 New criteria based on the revised AIH criteria were proposed by Zhang et al. and seemed to have a better sensitivity (Table S2).”
Diagnosis and management of primary biliary cirrhosis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.979792 · Cited by 24
“The two most widely used criteria for the diagnosis of PBC-AIH overlap syndrome are the Paris Study Group Criteria [123] and the International Autoimmune Hepatitis Group (IAIHG) criteria [124].”
MethodWu, H., Li, S., Wang, Q., Bao, H., Miao, Q., Xiao, X., Guo, C., Li, H., Ma, X., Qiu, D., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i6.737 · Cited by 24
PRIMARY BILIARY CIRRHOSIS, PRIMARY SCLEROSING CHOLANGITIS, AND AUTOIMMUNE CHOLANGITIS
Sherlock, S. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70098-2 · Cited by 26
Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis
Angulo, P. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)03237-3 · Cited by 23
“Until now, and to our knowledge, there have been only two reports of patients with typical PBC who evolved into AIH (7, 8) and one case report of a patient with AIH who further evolved into PBC (9).”
BackgroundUpdate on Primary Biliary Cirrhosis
Heathcote, J. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/989486 · Cited by 24
“The new term ‘overlap syndrome’ has added great confusion, and not much benefit has been gained from its various interpretations (5-7).”
Anti-mitochondrial M2 antibody-positive autoimmune hepatitis
TOMIZAWA, M., SHINOZAKI, F., FUGO, K., MOTOYOSHI, Y., SUGIYAMA, T., YAMAMOTO, S., KISHIMOTO, T., & ISHIGE, N. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2694 · Cited by 22
“The diagnosis of PBC‐AIH overlap syndrome was based on the Paris criteria (24).”
Fujinaga, Y., Namisaki, T., Takaya, H., Tsuji, Y., Suzuki, J., Shibamoto, A., Kubo, T., Iwai, S., Tomooka, F., Takeda, S., et al. (2021) · Medicine · doi:10.1097/md.0000000000027403 · Cited by 23
“Exclusion criteria were autoimmune overlap syndrome,([22]) use of immunosuppressive agents, and clinical findings suggestive of concomitant liver disease (i.”
BackgroundCurrent topics in autoimmune hepatitis
Muratori, L., Muratori, P., Granito, A., Pappas, G., Cassani, F., & Lenzi, M. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.05.019 · Cited by 22
“[63]).”
BackgroundIto, T., Ishigami, M., Morooka, H., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Nishimura, D., Tada, T., Yasuda, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74732-3 · Cited by 24
Laboratory Tests in Liver Disease
Vuppalanchi, R., & Chalasani, N. (2011) · Elsevier eBooks · doi:10.1016/b978-0-443-06803-4.00005-8 · Cited by 22
Clinical Significance of Autoantibodies to P53 Protein in Patients with Autoimmune Liver Diseases
Himoto, T., Yoneyama, H., Kurokohchi, K., Inukai, M., Masugata, H., Goda, F., Haba, R., Watanabe, S., Senda, S., & Masaki, T. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/890698 · Cited by 21
Muñoz-Espinosa, L. E., Alarcón, G., Mercado-Moreira, A. B., Cordero‐Pérez, P., Caballero, E. J., Avalos, V., Villarreal, G., Senties, K., Puente, D., Soto, J., et al. (2011) · Autoimmunity · doi:10.3109/08916934.2011.592884 · Cited by 21
Management of patients with difficult autoimmune hepatitis
Parker, R., Oo, Y. H., & Adams, D. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12450251 · Cited by 23
“There is now good evidence that patients with PBC associated with florid interface hepatitis respond to immunosuppressive therapy whereas those in whom the biliary feature predominates failed to respond to immunosuppression and should be treated with ursodeoxycholic acid alone [Chazouillères et al. 1998; Al-Chalabi et…”
BackgroundAutoimmune Hepatitis in the Asia-Pacific Area
Wang, Q., Li, Y., & Ma, X. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00032 · Cited by 25
“The Paris criteria (1998) include three AIH criteria and three PBC criteria.(105) Since serum ASMA positivity are less common and IgG concentrations are rare above 23 the upper limit of normal (ULN) in the Asia-Pacific area,(10) the diagnostic value of these AIH-PBC overlap syndrome criteria is probably not satisfacto…”
MethodLiu, Y., Han, K., Liu, C., Duan, F., Cheng, J., & Yang, S. T. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/5557814 · Cited by 25
“. erefore, our findings con-firm that patients with PBC-AIH progress rapidly to cirrhosis and, subsequently, liver failure [37].”
Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis
Namisaki, T., Moriya, K., Noguchi, R., Kitade, M., Kawaratani, H., Yamao, J., Mitoro, A., Yoshida, M., Sawai, M., Uejima, M., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12746 · Cited by 23
Autoimmune hepatitis and overlap syndromes
Vogel, A., Wedemeyer, H. H., Manns, M. P., & Strassburg, C. P. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.17.s3.33.x · Cited by 21
The Serological Profile of the Autoimmune Hepatitis/Primary Biliary Cirrhosis Overlap Syndrome
Efe, C., Pürnak, T., Özaslan, E., & Wåhlin, S. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.602 · Cited by 22
Heathcote, E. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04055-8 · Cited by 21
“But this figure is nevertheless higher than any other reports’— the highest being 10% using an abbreviated scoring system (4).”
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland
Beretta‐Piccoli, B. T., Stirnimann, G., Cerny, A., Semela, D., Hessler, R., Helbling, B., Stickel, F., Bakker, C. A. J. K.-D., Bihl, F. K., Giostra, E., et al. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8656-x · Cited by 22
Autoimmune Hepatitis – Primary Biliary Cirrhosis Overlap Syndrome
Bairy, I., Berwal, A., & Seshadri, S. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/25193.10242 · Cited by 23
“A complete clinical and biochemical response is achieved in patients after using combination therapy of UDCA and corticosteroids [5,8].”
BackgroundVariant and Specific Forms of Autoimmune Cholestatic Liver Diseases
Dalekos, G. Ν., & Gatselis, N. (2019) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-019-00550-9 · Cited by 23
Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience
Pape, S., Nevens, F., Verslype, C., Mertens, C., Drenth, J. P. H., & Tjwa, E. T. T. L. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001580 · Cited by 22
Cançado, G. G. L., Braga, M. H., Ferraz, M. L. G., Villela‐Nogueira, C. A., Terrabuio, D. R. B., Cançado, E. L. R., Nardelli, M. J., Faria, L. C., Gomes, N. M. D. F., Oliveira, E. M. G., et al. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100546 · Cited by 20
Variant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management
Weiler‐Normann, C., & Lohse, A. W. (2016) · Digestive Diseases · doi:10.1159/000444472 · Cited by 21
Recognizing autoimmune hepatitis: Scores help, but no more
Lohse, A. W. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.013 · Cited by 20
de Veer, R. C., van Hooff, M. C., Corpechot, C., Thorburn, D., Invernizzi, P., Lammers, W. J., Janssen, H. L. A., Battezzati, P. M., Nevens, F., Lindor, K. D., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002128 · Cited by 23
Graf, M., Lange, C. M., Langer, M., Schattenberg, J. M., Seeßle, J., Dietz, J., Vermehren, A., Michael, F. A., Mondorf, A. W., Zeuzem, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12227047 · Cited by 20
High seroprevalence of anti‐Hepatitis E antibodies in Austrian patients with autoimmune hepatitis
Eder, M., Straßl, R. P., Beinhardt, S., Stättermayer, A. F., Kozbial, K., Lagler, H., Holzmann, H., Trauner, M., & Hofer, H. (2018) · Liver International · doi:10.1111/liv.14005 · Cited by 19
Janik, M. K., Smyk, W., Kruk, B., Szczepankiewicz, B., Górnicka, B., Lebiedzińska, M., Potes, Y., Simões, I. C. M., Weber, S. N., Lammert, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03521-3 · Cited by 20
Metadata
- Authors
- Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Corresponding author
- Chazouillères, Olivier
- Venue
- Hepatology
- Published
- 1998-08
- Volume
- 28
- Issue
- 2
- Pages
- 296-301
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2056147648
- Semantic Scholar
- e5878dda2aeaf614ad753e5c66ea3a752edfb605
- Cited by
- 746
- References
- 34
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 37 · 2023: 37 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 27 · 2018: 38 · 2017: 31 · 2016: 28 · 2015: 36 · 2014: 32 · 2013: 32 · 2012: 33
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6240 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune hepatitis, overlap syndrome, ursodeoxycholic acid, corticosteroids, combination therapy, treatment resistance, anti-smooth muscle antibodies, antimitochondrial antibodies, cholestasis, liver fibrosis, IgG, anti-amyloid antibodies, remission, disease flares, bile duct lesions
- MeSH terms
- Adrenal Cortex Hormones, Adult, Aged, Cholagogues and Choleretics, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Liver Cirrhosis, Biliary, Male, Middle Aged, Syndrome, Ursodeoxycholic Acid, Treatment Outcome, Hepatitis, Autoimmune
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.